LidoStakeAddict

Just caught Kier Group's H1 results and the numbers look pretty solid. Profit before tax jumped 14% to 32.6 million pounds, and they're clearly doing something right operationally - adjusted operating profit grew 6.6% to 71m. The EPS story is interesting too, with basic earnings per share up 24% to 5.7p.
What caught my eye though was the dividend decision. Kier bumped the interim payout to 2.6p per share, which is a 30% year-on-year increase. That's a pretty confident signal from management, especially when you look at the revenue side - up 2% to 2.01bn on a statutory basis. Adjusted revenue c

Just caught Zebra Technologies popping off 20% in early trading Thursday - always interesting to see what actually moves the needle in this market. Turns out their Q4 results were solid enough, but the real story is management's guidance for next quarter came in way hotter than what Wall Street was expecting.
So here's what happened: Revenue hit $1.48 billion, up about 10.6% year-over-year, with adjusted earnings at $4.33 per share. Nothing earth-shattering on its own - basically in line with consensus. But then they guided for Q1 at roughly $1.48 billion in revenue and $4.18 in adjusted EPS,

Just caught wind of an interesting biotech move that could reshape Esperion's growth trajectory. ESPR announced it's acquiring Corstasis Therapeutics for $75 million upfront, with another $180 million potentially coming through if they hit certain milestones. What's catching my attention is the product they're getting - Enbumyst, which is basically the only FDA-approved nasal spray diuretic for treating fluid buildup in heart failure and liver/kidney disease patients.
So here's why this matters. Esperion already has Nexletol and Nexlizet doing solid work in the cholesterol/cardiovascular space

Just caught that Braidwell trimmed their Xenon stake pretty hard in Q4 - sold off nearly 1.8M shares for about $75 million. Position went from meaningful to just 2.6% of their fund, which is honestly telling.
The timing is interesting because Xenon's Phase 3 data for azetukalner was supposed to drop in March (we're past that now), so either they're getting ahead of potential downside or just rebalancing risk. Stock's been pretty flat - only up like 6% over the past year, which is weak for biotech.
What gets me is they're not bailing entirely, just right-sizing. Xenon's still sitting on a bunch

Been reading about how Dave Ramsey and Kevin O'Leary approach debt, and honestly it's interesting how two guys with completely different vibes agree on the core strategy. Like, Ramsey would never touch crypto but O'Leary is all in, yet they're saying basically the same thing about getting out of debt.
The advice is pretty straightforward: stop spending on stuff you don't actually need. Sounds simple but it's wild how many people miss this. Dave Ramsey breaks it down into actual steps - get on a budget, cover your basics first (food, utilities, shelter, transport), then cut the rest. No new deb

So Claar Advisors just dropped $7.31M on Callaway Golf in Q4 2025. That's 626k shares. Not exactly a massive fund position - only 2.14% of their AUM - but still interesting that someone's betting on golf equipment demand staying strong.
Callaway's up 108% over the past year, which is wild. I guess people really are upgrading their clubs. The whole golf index has been performing better than most expected, especially with Topgolf doing its thing in the entertainment space.
Here's the thing though - the company's margins are getting hit by tariffs and costs. They're banking on new product launche

Just noticed The Trade Desk absolutely popped off today - up 18% on some pretty interesting developments. The stock hit $29.79 and honestly the trading volume was insane, like 82 million shares moving around. If you're wondering how to trade stock in this kind of environment, days like this are exactly why people pay attention to both the news and the actual price action.
So what happened? Apparently the company's been having early talks with OpenAI about helping them roll out ads on their platform. That alone got people excited, but then the CEO Jeff Green went and bought 6 million shares him

Just caught that Vertex had a solid day on Thursday, up almost 6% after Goldman Sachs put out a pretty bullish take on it. The analyst Adam Hotchkiss basically said the stock could hit $23 a share, which is like 80% higher than where it was trading. That's a pretty bold call. What's interesting about Vertex is it operates in the fintech space doing e-invoicing and other services, and apparently the analyst thinks their AI investments could really pay off down the line. The company's been around since 1978 so it's got some history, but the stock got beaten down pretty hard recently which made i

Just been looking at Mercury General (MCY) and it's caught my attention lately. The stock is up nearly 5% over the past week while the insurance sector only gained about 1.2%, so it's definitely outperforming. What's interesting is the longer-term picture too - up around 67% over the past year compared to the S&P 500's 16.8%. That kind of divergence usually means something is working.
The earnings picture is helping build momentum here. Over the last two months, analysts have been raising their full-year estimates rather than cutting them. The consensus moved from $8.40 to $9.00, which is a so

So I finally got out of debt recently, and honestly? Talking about it has been way more helpful than I expected. Turns out most people are dealing with this too, which is kind of a relief.
Here's what got me thinking though. Total consumer debt in America is sitting at $16.5 trillion right now. That's a record high according to the New York Fed. When you break that down, the average American household is carrying around $96,371 in debt. That's genuinely wild when you consider the median full-time worker makes about $55,640 a year. So yeah, a lot of people owe more than they actually earn annua

Just saw that Agios got PYRUKYND approved in the UAE for thalassemia patients. Interesting move - it's the only drug approved there for this specific thalassemia profile, which is kind of a big deal for patients who actually need it.
The approval is based on their Phase 3 trials (ENERGIZE and ENERGIZE-T), so at least it's backed by solid data. They already have it approved in the US and Europe, and apparently they partnered with NewBridge Pharmaceuticals back in 2024 to push it through the GCC region - Saudi Arabia, UAE, Kuwait, Qatar, Oman, Bahrain.
What's interesting is they're still waiting

Just caught something interesting in the market right now. You know how stock splits usually signal confidence? Well, Booking Holdings announced a 25-to-1 split back in February and the stock actually tanked more than 5% since then. Most people are panicking about AI disrupting travel bookings, but I think they're missing the bigger picture here.
Let me break down why this might actually be one of the cheap shares to buy at the moment. Everyone's worried that AI chatbots will let people book flights and hotels without needing Booking anymore. Fair concern on the surface, but here's what most i

Just been reading up on student loan servicers and honestly, the landscape is getting pretty complicated with all these policy changes happening. So I'm looking at this list of student loan servicers that are actually federal-approved, and the main ones everyone talks about are Aidvantage, Nelnet, and MOHELA.
Aidvantage seems solid if you're trying to manage different repayment plans—they handle the standard stuff plus income-driven options and military benefits. Nelnet's interesting because they also do private loans on top of federal servicing, with rates floating around 3.47% to 5.81% depen

Been seeing more people talk about peer to peer lending lately, and honestly there's a lot to unpack here. It's basically this online marketplace that connects people who need money with people who want to invest it. No bank middleman, just algorithms doing the matching work.
So here's the thing - if you're a borrower, the appeal is pretty straightforward. You can get anywhere from $1,000 to $50,000 depending on what you need, usually over 1-5 years with fixed monthly payments. The whole process is online and relatively fast, which beats waiting around at a bank branch. Plus if traditional ban

Just had someone ask me if buying Shiba Inu today could set them up for life. Honestly, I get this question more often than you'd think, especially when people see historical returns. Let me break down why I'm skeptical.
Yeah, SHIB went up like 97,000% over five years. That's insane on paper. But here's the thing - it's currently trading 93% below its October 2021 peak. So those massive gains? Mostly in the rearview mirror.
If you're looking to 100x your money to actually set yourself up for life, that's a specific goal. Shiba Inu would need to hit a market cap around $380 billion to pull that

Plug Power had their Q4 earnings call back in early March if anyone missed it. The hydrogen fuel cell power company hosted the discussion at 4:30 PM ET on March 02, 2026. If you want to catch the replay or were looking at the numbers, you could dial in at 877-407-9221 or +1 201-689-8597. Pretty standard earnings season stuff, but worth checking out if you're tracking companies in the clean power space. Plug Power's been interesting to watch with all the hydrogen fuel developments happening.

Just been thinking about the quantum computing hype lately, and there's something worth paying attention to here that most people are probably missing.
Everyone's fixated on pure-play quantum companies like D-Wave and IonQ - they're the headline grabbers, sure. But here's the thing: those companies are still burning cash, heavily dependent on external funding, and meaningful commercialization is still years away. The volatility in their stock prices can be brutal.
Meanwhile, there's a more reliable play sitting right in front of us that most investors overlook when it comes to quantum exposure

Just been doing some research on used cars and honestly, hitting 100k miles seems to be a real turning point for certain models. Like, I kept seeing the same cars pop up in forums where people were complaining about major repairs right around that mileage. Pretty wild how specific some of these issues are.
So apparently Nissan Altimas have this transmission problem that kicks in once they cross 100k - not ideal when you're looking at a reliable daily driver. Then there's the BMW 3 Series, which looks gorgeous but demands serious maintenance money after that milestone. Land Rovers apparently lo

Palantir just posted solid earnings back in early February and the stock initially spiked, but here's the thing - it's still down about a third from its November highs. So naturally everyone's asking if this is the moment to buy the dip. Let me break down what I'm actually seeing here.
At its core, Palantir builds data integration platforms that help massive organizations turn their information chaos into something actually useful. They've got Gotham for government work and Foundry for commercial clients - basically operating systems that pull data from everywhere and make it coherent. Then AI

Just realized how complicated New Jersey's corporate tax situation has become. If you're running a business in the state or planning to expand there, the tax structure is definitely worth understanding before you commit.
So here's what's actually going on with the New Jersey corporate tax rate. The state uses a graduated system based on your entire net income. If you're making $50,000 or less, you're looking at 6.5%. Jump to over $50,000 but under $100,000, and it goes to 7.5%. Anything over $100,000 gets hit with 9%. But here's the kicker—if your taxable net income hits over $10 million, ther